MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562339 | Name: Ridaifen-B
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ridaifen-B is a tamoxifen derivative. It acts by inducing Bcl-2 independent autophagy without estrogen receptor involvement.

Chemical Structure

Ridaifen-B
Ridaifen-B
CAS#886465-70-9

Theoretical Analysis

MedKoo Cat#: 562339

Name: Ridaifen-B

CAS#: 886465-70-9

Chemical Formula: C34H42N2O2

Exact Mass: 510.3246

Molecular Weight: 510.72

Elemental Analysis: C, 79.96; H, 8.29; N, 5.49; O, 6.27

Price and Availability

Size Price Availability Quantity
5mg USD 350.00
10mg USD 610.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Ridaifen B; Ridaifen-B; RidaifenB;
IUPAC/Chemical Name
1-[2-[4-[2-Phenyl-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]but-1-enyl]phenoxy]ethyl]pyrrolidine
InChi Key
XQQWCGJGUHJSLR-UHFFFAOYSA-N
InChi Code
InChI=1S/C34H42N2O2/c1-2-33(28-10-4-3-5-11-28)34(29-12-16-31(17-13-29)37-26-24-35-20-6-7-21-35)30-14-18-32(19-15-30)38-27-25-36-22-8-9-23-36/h3-5,10-19H,2,6-9,20-27H2,1H3
SMILES Code
CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN3CCCC3)C=C2)/C4=CC=C(OCCN5CCCC5)C=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Ridaifen-B is an antagonist of estrogen receptor α (ERα; IC50 = 52.4 nM), an inverse agonist of cannabinoid (CB) receptor 2 (CB2; Ki = 43.7 nM), and a derivative of tamoxifen. It is selective for CB2 over CB1 receptors (Ki = 732 nM). Ridaifen-B was designed to be cytotoxic to cancer cells independent of ER binding; it inhibits growth of ER-positive and ER-negative cells in a panel of 39 cancer cell lines (GI50s = 0.20-2.14 µM). It induces apoptosis and autophagy in ER-negative Jurkat cells when used at a concentration of 0.4 µM.4 Ridaifen-B decreases nitric oxide (NO) production and protein levels of IL-1α and IL-6 in LPS-stimulated RAW 264.7 cells when used at a concentration of 1 µM.
In vitro activity:
This study suggests that autophagy was induced against apoptosis caused by mitochondrial dysfunction in ridaifen-B, so the combination of autophagy inhibitor and anticancer-drug can be effective for cancer treatment. Reference: Biol Pharm Bull. 2019;42(3):401-410. https://pubmed.ncbi.nlm.nih.gov/30828072/
In vivo activity:
The findings of this study suggest the inhibition of both FGFR2 and mTOR by the ponatinib-ridaforolimus combination may provide a new therapeutic strategy to treat advanced endometrial cancers with dual pathway dysregulation. Reference: Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. https://pubmed.ncbi.nlm.nih.gov/23468082/
Solvent mg/mL mM
Solubility
DMF 20.0 39.16
DMSO 2.0 3.92
Ethanol 20.0 39.16
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 510.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Iwasawa T, Shinomiya T, Ota N, Shibata N, Nakata K, Shiina I, Nagahara Y. Novel Ridaifen-B Structure Analog Induces Apoptosis and Autophagy Depending on Pyrrolidine Side Chain. Biol Pharm Bull. 2019;42(3):401-410. doi: 10.1248/bpb.b18-00643. PMID: 30828072. 2. Nagahara Y, Takeyoshi M, Sakemoto S, Shiina I, Nakata K, Fujimori K, Wang Y, Umeda E, Watanabe C, Uetake S, Yamori T, Dan S, Yoshimi Y, Shinomiya T, Ikekita M. Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement. Biochem Biophys Res Commun. 2013 Jun 14;435(4):657-63. doi: 10.1016/j.bbrc.2013.05.040. Epub 2013 May 18. PMID: 23688426. 3. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. PMID: 23468082.
In vitro protocol:
1. Iwasawa T, Shinomiya T, Ota N, Shibata N, Nakata K, Shiina I, Nagahara Y. Novel Ridaifen-B Structure Analog Induces Apoptosis and Autophagy Depending on Pyrrolidine Side Chain. Biol Pharm Bull. 2019;42(3):401-410. doi: 10.1248/bpb.b18-00643. PMID: 30828072. 2. Nagahara Y, Takeyoshi M, Sakemoto S, Shiina I, Nakata K, Fujimori K, Wang Y, Umeda E, Watanabe C, Uetake S, Yamori T, Dan S, Yoshimi Y, Shinomiya T, Ikekita M. Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement. Biochem Biophys Res Commun. 2013 Jun 14;435(4):657-63. doi: 10.1016/j.bbrc.2013.05.040. Epub 2013 May 18. PMID: 23688426.
In vivo protocol:
1. Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7. PMID: 23468082.
1: Murata T, Komukai K, Semba Y, Murata E, Sato F, Takano T, Tsuchiya K, Matsuda C, Sakai A, Yoneoka A, Takahashi S, Nagahara Y, Shiina I. Synthesis of BODIPY FL-tethered ridaifen-B, RID-B-BODIPY, and its localization in cancer cells. Front Chem. 2024 Aug 23;12:1451468. doi: 10.3389/fchem.2024.1451468. PMID: 39246721; PMCID: PMC11377228. 2: Cooper L, Schafer A, Li Y, Cheng H, Medegan Fagla B, Shen Z, Nowar R, Dye K, Anantpadma M, Davey RA, Thatcher GRJ, Rong L, Xiong R. Screening and Reverse- Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Oct 8;63(19):11085-11099. doi: 10.1021/acs.jmedchem.0c01001. Epub 2020 Sep 22. PMID: 32886512; PMCID: PMC7904233. 3: Iwasawa T, Shinomiya T, Ota N, Shibata N, Nakata K, Shiina I, Nagahara Y. Novel Ridaifen-B Structure Analog Induces Apoptosis and Autophagy Depending on Pyrrolidine Side Chain. Biol Pharm Bull. 2019;42(3):401-410. doi: 10.1248/bpb.b18-00643. PMID: 30828072. 4: Hasegawa G, Akatsuka K, Hiruma K, Suda K, Yokoe Y, Mizusawa A, Ota N, Shibata N, Tsuchiya K, Hayashi M, Shiina I, Shimonaka M. Anti-proliferative effect of ridaifen-B on hepatoma cells. Biomed Rep. 2018 Aug;9(2):175-180. doi: 10.3892/br.2018.1112. Epub 2018 Jun 13. PMID: 30013780; PMCID: PMC6036825. 5: Franks LN, Ford BM, Fujiwara T, Zhao H, Prather PL. The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. Toxicol Appl Pharmacol. 2018 Aug 15;353:31-42. doi: 10.1016/j.taap.2018.06.009. Epub 2018 Jun 12. PMID: 29906493; PMCID: PMC6487498. 6: Nagahara Y, Takeyoshi M, Sakemoto S, Shiina I, Nakata K, Fujimori K, Wang Y, Umeda E, Watanabe C, Uetake S, Yamori T, Dan S, Yoshimi Y, Shinomiya T, Ikekita M. Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement. Biochem Biophys Res Commun. 2013 Jun 14;435(4):657-63. doi: 10.1016/j.bbrc.2013.05.040. Epub 2013 May 18. PMID: 23688426. 7: Tsukuda S, Kusayanagi T, Umeda E, Watanabe C, Tosaki YT, Kamisuki S, Takeuchi T, Takakusagi Y, Shiina I, Sugawara F. Ridaifen B, a tamoxifen derivative, directly binds to Grb10 interacting GYF protein 2. Bioorg Med Chem. 2013 Jan 1;21(1):311-20. doi: 10.1016/j.bmc.2012.10.037. Epub 2012 Oct 29. PMID: 23199482. 8: Nagahara Y, Shiina I, Nakata K, Sasaki A, Miyamoto T, Ikekita M. Induction of mitochondria-involved apoptosis in estrogen receptor-negative cells by a novel tamoxifen derivative, ridaifen-B. Cancer Sci. 2008 Mar;99(3):608-14. doi: 10.1111/j.1349-7006.2007.00709.x. Epub 2007 Dec 19. PMID: 18167132; PMCID: PMC11159952.